GlassScriptPhysician profile
Kovosh Dastan
NPI 1912403734
$23,163.13
in general payments reported to CMS, 2019-2025
9 companies · $630 in 2025
The $630 reported for 2025 was more than what 82% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $464 · 2023: $17K · 2024: $4,987 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $15K · Travel and Lodging: $4,343 · Food and Beverage: $3,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $15,000.00 |
| Travel and Lodging | $4,342.58 |
| Food and Beverage | $3,356.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $21,894.73 | 2022-2025 | Synchromedii, Intellis Adaptivestim, Vanta Adaptivestim |
| Boston Scientific Corporation | $562.30 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $477.78 | 2024-2025 | Proclaim, Eterna, Octrode |
| Spr Therapeutics, INC | $108.03 | 2024-2025 | Sprint Pns System |
| Collegium Pharmaceutical, INC. | $31.37 | 2025 | Xtampza |
| Globus Medical, INC. | $29.65 | 2025 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.15 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $16.37 | 2025 | Iovera |
| Avanos Medical | $15.75 | 2024 | Coolief* Cooled Radiofrequency |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kovosh Dastan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.